Patent, page-3

It's a good patent application because it is broad .... covering the treatment and prevention of midkine related disorders.

The CDY therapeutic strategy is very straight forward. Where midkine levels are raised by a cancer or another illness, the antibody can be used to bring it back down. This is how, where and why CDY's proprietary antibodies will soon have global application.

The clock does indeed tick slowly noting that the application was filed March 2012 but what the hey... all that matters is that the IP is protected and updated as required from a multiplicity of broad and narrow tangents.

Cellmid will be well prepared for its pre-IND meeting in the near future just as Quest Diagnostics will be talking to US regulators when the final Luminex data is compiled and analysed. There will also be FDA meetings in relation to MK Elisa. Exciting times!

cheers